All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Cell Type | Target | HLA | Epitope | Inquiry & Datasheet |
TCRJ-CQ150 | Anti-HMHA1 (VLHDDLLEA) T Cell Receptor (clone 15), Jurkat Cell Line | T lymphocyte | HMHA1 | HLA-A2 | VLHDDLLEA | |
TCRJ-CQ151 | Anti-HMHA1 (VLHDDLLEA) T Cell Receptor (clone 3HA15), Jurkat Cell Line | T lymphocyte | HMHA1 | HLA-A2 | VLHDDLLEA | |
TCRJ-CQ152 | Anti-HMHA1 (VLHDDLLEA) T Cell Receptor (clone 5W38), Jurkat Cell Line | T lymphocyte | HMHA1 | HLA-A2 | VLHDDLLEA | |
TCRJ-CQ153 | Anti-HMHA1 (VLHDDLLEA) T Cell Receptor (clone HA1.M7), Jurkat Cell Line | T lymphocyte | HMHA1 | HLA-A*0201 | VLHDDLLEA | |
TCRJ-CQ154 | Anti-HMHA1 (VLHDDLLEA ) T Cell Receptor (clone KP7), Jurkat Cell Line | T lymphocyte | HMHA1 | HLA-A2 | VLHDDLLEA | |
XS-0623-ZP159 | Anti-HMHA1 TCR-NK Cells | TCR-NK | HMHA1 |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION